SCHEMBL2173400

SCHEMBL2173400

CCS(=O)(=O)Nc1cccc(Oc2cc(F)cc(Nc3ccc(I)cc3F)c2C(N)=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 20/20 1.00
CA2 P00918 4/20 0.82
CA1 P00915 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495086 0.91 MAP2K1 (1.00) MAP2K1CA2CA1
SCHEMBL1111411 0.91 MAP2K1 (0.85) MAP2K1CA2CA1
SCHEMBL1111449 0.91 MAP2K1 (0.83) MAP2K1CA2CA1
SCHEMBL1111359 0.90 MAP2K1 (1.00) MAP2K1CA2CA1
SCHEMBL1111479 0.90 MAP2K1 (1.00) MAP2K1CA2CA1
SCHEMBL1111467 0.90 MAP2K1 (1.00) MAP2K1CA2CA1
SCHEMBL29425473 0.90 MAP2K1 (1.00) MAP2K1CA2CA1
SCHEMBL1111401 0.89 MAP2K1 (0.85) MAP2K1CA2CA1
SCHEMBL1111036 0.89 MAP2K1 (0.88) MAP2K1CA2CA1
SCHEMBL2174993 0.89 MAP2K1 (1.00) MAP2K1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993630-B2 Substituted sulphonamido phenoxybenzamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-31 US claimed
EP-2346818-B1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER IP GMBH (DE) 2012-12-05 EP claimed
US-20110218219-A1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-08 US claimed
EP-2346818-A2 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES Bayer Schering Pharma AG (DE) 2011-07-27 EP claimed
WO-2010051933-A2 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-14 WO claimed
US-8993630-B2 Substituted sulphonamido phenoxybenzamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-31 US disclosed
US-8993630-B2 Substituted sulphonamido phenoxybenzamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-31 US disclosed
EP-2346818-B1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER IP GMBH (DE) 2012-12-05 EP disclosed
EP-2346818-B1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER IP GMBH (DE) 2012-12-05 EP disclosed
US-20110218219-A1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-08 US disclosed
US-20110218219-A1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-08 US disclosed
EP-2346818-A2 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES Bayer Schering Pharma AG (DE) 2011-07-27 EP disclosed
WO-2010051933-A2 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-14 WO disclosed
WO-2010051933-A2 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218219-A1 SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES CCNB3, MKI67, RB1 MAP2K1 2618/4885CA2 1414/4885CA1 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.